RAG2 and acute myeloid leukemia: To examine the impact of exogenous type I IFN on the efficacy of SOC chemotherapy, we generated AML xenografts by intravenously injecting Rag2-/- mice (which lack B and T cells) with 2.5 × 106 human wild-type (WT) KASUMI-1 AML cells (Fig. 4A).